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One  option  for  achieving  global  polio  eradication  is  to replace  the  oral  poliovirus  vaccine  (OPV),  which
has  the  risk  of  reversion  to wild-type  virulence,  with  the inactivated  poliovirus  vaccine  (IPV)  vaccine.
Adjuvants  and  alternate  routes  of immunization  are promising  options  that may  reduce  antigen  dose
in IPV vaccinations,  potentially  allowing  dose  sparing  and  cost  savings.  Use of  adjuvants  and  alternate
routes  of  immunization  could  also  help  promote  mucosal  immunity,  potentially  mimicking  the  protec-
tion  against  intestinal  virus  shedding  seen  with  OPV.  In  the  current  study,  we examined  the  impact  of
combining  the novel  adjuvant  dmLT  with  trivalent  IPV for dose  sparing,  induction  of mucosal  immunity
and  increasing  longevity  of anti-poliovirus  (PV)  responses  in  a mouse  model  following  either  intradermal
(ID)  or  intramuscular  (IM)  delivery.
We found  that non-adjuvanted  ID delivery  was  not  superior  to  IM delivery  for  fractional  dose  spar-
ing,  but  was  associated  with  development  of  mucosal  immunity.  Vaccination  with  IPV +  dmLT  promoted
serum  anti-PV  neutralizing  antibodies  with  fractional  IPV doses  by either  IM or ID  delivery,  achieving  at
least  ﬁve-fold  dose  sparing  above  non-adjuvanted  fractional  doses.  These  responses  were  most  noticeable
with the PV1  component  of  the  trivalent  vaccine.  dmLT  also  promoted  germinal  center  formation  and
longevity  of serum  anti-PV  neutralizing  titers.  Lastly,  dmLT  enhanced  mucosal  immunity,  as  deﬁned  by
fecal  and  intestinal  anti-PV  IgA  secretion,  when  included  in  IPV  immunization  by ID  or IM  delivery.  These
studies  demonstrate  that  dmLT  is  an  effective  adjuvant  for  either  IM  or  ID  delivery  of IPV.  Inclusion  of
dmLT  in  IPV immunizations  allows  antigen  dose  sparing  and enhances  mucosal  immunity  and  longevity
of  anti-PV  responses.
ublis©  2015  The  Authors.  P
. Introduction
Polio is a highly infectious disease with no reservoir outside
f its human host and is, therefore, a target for global eradica-
ion. Poliovirus spreads through contaminated food and water and
erson-to-person contact, infecting susceptible populations (e.g.,
hildren < 5 years) where intestinal virus replication and shedding
Abbreviations: IPV, formalin inactivated poliovirus vaccine; OPV, oral poliovirus
accine; dmLT, double mutant heat-labile enterotoxin from E. coli LT(R192G/L211A);
V, poliovirus; ID, intradermal; IM,  intramuscular; DU, D antigen units; PP, Peyer’s
atches.
∗ Corresponding author. Tel.: +1 504 988 5070; fax: +1 504 988 7769.
E-mail addresses: enorton@tulane.edu (E.B. Norton), dbauer3@tulane.edu
D.L. Bauer), wiw4@cdc.gov (W.C. Weldon), mbo2@cdc.gov (M.S. Oberste),
braud@tulane.edu (L.B. Lawson), jclemen@tulane.edu (J.D. Clements).
ttp://dx.doi.org/10.1016/j.vaccine.2015.02.069
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
occur over a period of weeks [1]. While the majority of infec-
tions are asymptomatic or cause mild disease, ∼0.5% of infections
result in acute onset of ﬂaccid paralysis leading to permanent
loss of muscle function, limb use, and, in severe cases, respira-
tory control and death [1]. Vaccination and a global eradication
effort have successfully dropped the burden of disease from an esti-
mated 350,000 cases of paralytic polio worldwide in 1988 to 416
cases in 2013 [1] and polio now remains endemic in only three
countries [2]. Vaccination is key to virus control, as polio disease is
rapidly re-established after low or disrupted vaccination coverage.
For instance, disease outbreaks may  occur during political distur-
bances and then spread into adjacent communities, such as those
in the horn of Africa (2008–2013) and in Syria (2013–2014) [2,3].
Immunization programs use either the live, attenuated oral
polio vaccine (OPV) or a formalin-inactivated polio vaccine (IPV),
both trivalent for serotypes-1, -2 and -3. Most of the developed
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.7. Data analysis
Statistical analysis was  performed using Prism (GraphPad Soft-910 E.B. Norton et al. / Vac
orld uses the injectable IPV vaccine which costs ∼US$1.00 per
ose in GAVI eligible countries. However, OPV is preferred for
eveloping countries because it is less expensive, at ∼US$0.15 per
ose, and easier to administer in less advanced health-care sett-
ngs. As a live attenuated vaccine, OPV replicates in the intestines of
accine recipients and promotes intestinal resistance to poliovirus
e-infection (i.e., mucosal immunity) [4]. Herd immunity also
ncreases with OPV, including expanding community coverage
eyond vaccinated individuals, presumably through OPV fecal
hedding [5]. However, OPV strains can replicate in areas with
ncomplete vaccine coverage, enabling step-wise reversion to wild-
ype virulence and transmissibility (vaccine-derived poliovirus or
DPV) as seen most frequently for type-2 OPV. OPV can also
eplicate and be shed in the feces of immunocompromised hosts
reating poliovirus reservoirs from which strains with wild-type
irulence can later emerge [2]. While bivalent OPV lacking the type-
 strain has been developed to help address type-2 VDPV, use of
PV should be discontinued in order to completely eradicate polio.
 major part of current global polio eradication efforts is to reduce
he cost of IPV and improve the existing IPV formulation through
ose sparing, addition of appropriate adjuvants, and induction of
ucosal immunity to reduce intestinal virus replication and sub-
equent fecal shedding [6–9].
The adjuvant LT(R192G/L211A), or dmLT, is a detoxiﬁed version
f the heat-labile enterotoxin of Escherichia coli, with two  mutations
n its A-subunit [10] that remove the enterotoxicity but preserve
he adjuvanticity of the molecule. dmLT appears to induce a cAMP-
ependent danger signal combined with a B-subunit GM1-binding
ignal to activate the immune system. Unlike its parent molecule,
mLT has no observable gastrointestinal toxicity in either ani-
als or humans, but is still an effective mucosal adjuvant [10–13].
accines including dmLT have improved immune responses to bac-
erial and viral antigens following oral, sublingual, transcutaneous,
ntradermal and intramuscular delivery [12–23]. Notably, we have
lso recently shown increased viral neutralization titers with a full
ose of IPV delivered sublingually within a thermoresponsive gel
ncluding dmLT [19]. The objective of the current study was  to eval-
ate whether intradermal (ID) or intramuscular (IM) delivery of
PV in combination with dmLT could reduce the required dose or
umber of doses of an existing IPV vaccine and whether this novel
djuvant could promote mucosal immunity following parenteral
mmunization.
. Materials and methods
.1. Virus and adjuvant reagents
Inactivated viral stocks Brunhilde PV1, MEF-1 PV2 and Saukett
V3 (977, 1260 and 1860 D-antigen units (DU)/ml), respectively,
nd premixed trivalent IPV (327 Brunhilde PV1, 70 MEF-1 PV2, and
79 Saukett PV3 DU/ml) were obtained from Statens Serum Institut
SSI, Copenhagen, DK). Individual PV-types were used for immuno-
ogical analysis. All immunizations were performed with premixed
rivalent IPV as supplied by SSI so the ratio of PV-types remains the
ame when different doses are administered. dmLT was  prepared
nder GMP  conditions by Walter Reed Army Institute of Research
Washington, DC) and obtained from PATH-EVI.
.2. Animals, immunizations and sample collections
Female BALB/c mice aged 6–8 weeks were purchased from
harles River Laboratories and housed in ﬁlter-top cages under
terile conditions. All animal studies were approved by the Tulane
niversity Institutional Animal Care and Use Committee. Groups of
–10 animals each were immunized by ID or IM injection with 50 l3 (2015) 1909–1915
of formulations in M199 (Gibco) or saline. Immunizations were
performed 1–3 times at 3-week intervals prior to CO2 euthana-
sia for sample collection, including serum, spleens, colon-derived
fecal pellets, and Peyer’s patches (PP). Fecal pellets were weighed,
homogenized in 1.5 ml  PBS – 0.05% Tween 20 containing a pro-
tease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN), and
the supernatants collected. PP were excised after rinsing the intes-
tine with 10 ml  cold saline. After weighing, PP were plated with
400 l 10% RPMI in a 24-well tissue culture plate and incubated
at 5% CO2 at 37 ◦C. After 7 days, supernatants were harvested and
stored at −20 ◦C.
2.3. Antibody ELISAs
Antigen-speciﬁc IgG and IgA ELISAs were performed similar to
methods previously described [10,12] using Linbro/Titertek 96-
well U-shaped plates (MP  Biomedicals, Santa Ana, CA, 76-341-05)
coated at 1:50 with PV antigens or dilutions of puriﬁed mouse stan-
dards, speciﬁcally IgG1-  (Sigma M9269) or IgA- (Sigma M1421).
Detection by IgG ELISAs was  performed using AKP-conjugated anti-
mouse IgG (Sigma A1902). Detection by IgA ELISAs was performed
using HRP-conjugated anti-mouse IgA (SouthernBiotech, Birming-
ham, AL, 1040-05) and TMB  Substrate (KPL 50-76-00). Results were
expressed as ELISA units/ml (EU/ml) using an average of three sam-
ple dilutions closest to the midpoint of the standard curve.
2.4. Poliovirus neutralization
Neutralizing antibody titers against Brunhilde PV1, MEF-1 PV2
and Saukett PV3 were measured as described previously [19,24].
Detection by this assay ranges from 2.5 log2, or “negative,” to 10.5
log2, as highest tested value; a log2 titer of ≥3 is considered pro-
tective.
2.5. Flow cytometry
Spleens were homogenized using C-tubes (Invitrogen) and ﬁl-
tered into suspension, stained and analyzed by ﬂow cytometry as
previously described [12]. Staining antibodies included anti-mouse
CD3-eFlour450, GL7-FITC (eBioscience, San Diego, CA), CD4-BV510
(BioLegend, San Diego, CA), and CD19-PE-Texas Red (Invitrogen).
2.6. Immunoblot
Blots were made using a slot blot apparatus (Hybri-slot vacuum
apparatus, Life Technologies, Grand Island, NY) coated with 10 DU
of PV1, 2 or 3 on a PVDF membrane and blocked with 5% skim milk
in PBS. Fecal samples (200 l) were diluted in 800 l PBS-0.05%
Tween 20 with 5% skim milk and added to an 8-rectangular well
plate containing a test blot. Following overnight incubation at 4 ◦C,
each blot was  washed then treated with anti-mouse IgA-HRP. Blots
were developed with ECL substrate (Invitrogen) and imaged with
ImageQuant LAS-4000 imaging system (GE). Images were quanti-
ﬁed for band integrated density units (IDU) per ml  using ImageJ, an
open source image processing and analysis software [25].ware v6, La Jolla, CA). Data were analyzed by Spearman’s Rank Order
Correlation Coefﬁcient (r) analysis and one-way ANOVA analysis
with Tukey’s multiple comparison post hoc test or Dunn’s multiple
comparison post hoc test for nonparametric data.
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Fig. 1. Poliovirus serum IgG and neutralization titers following IM or ID immunization. Animals (n = 7–10) were immunized twice (days 0 and 21) with the indicated IPV dose
(DU)  via IM delivery or ID delivery with or without dmLT (g). Serum collected 2 weeks after the last immunization was analyzed by ELISA (A) or in vitro virus neutralization
(B)  against each vaccine poliovirus strain: Brunhilde type-1 (top), MEF-1 type-2 (middle) and Saukett type-3 (bottom). Serum IgG values are mean + SEM with signiﬁcance
indicated as *P ≤ 0.05, **P ≤ 0.01 or ***P ≤ 0.001 versus naïve control for each virus serotype or as ¶P ≤ 0.05 versus 5 DU IM group using Tukey’s multiple comparison post
hoc  test. Virus neutralization titers were determined in triplicate using median cell culture infectious dose (CCID50) measurements with the ﬁnal titer estimated by the
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urrent human dose.
. Results
The trivalent IPV vaccine is traditionally delivered via three IM
njections containing 40 DU PV1, 8 DU PV2 and 32 DU PV3 each and
sually reported based on type-1 content with the understanding
hat the ratio of the constituents remains constant (40:8:32). Dose-
paring strategies can either reduce the number of doses or the
mount of antigen delivered by each immunization. ID delivery has
een suggested as the best parenteral route to achieve dose sparing
ue to the density of antigen-presenting cells in the skin (com-
ared to muscle tissue) available to promote vaccine immunity
8]. Promising clinical results have shown dose sparing of several
uman vaccines, including IPV, by switching to ID from IM or sub-
utaneous delivery [26–28]. For these reasons, in our studies we
ompare both IM and ID routes.
.1. Dose sparing and adjuvanticity
We  ﬁrst evaluated the antibody responses following vaccination
ith fractional doses of IPV comparing IM and ID delivery. For these
urposes, 5 DU IPV based on PV1 content was set as a “full” mouse
ose for comparative purposes. This dose was chosen based on
xperiments that showed mid-point antibody titers with IPV at this 10.5 log2, as highest tested value, and is shown as median bars with interquartile
 hoc test. Dotted line placed at the median titer in response to 5 DU IPV, or 1/8th of
dose compared to 0.1, 1, 10 and 15 DU of IPV (Fig. 1A). Our goal then
was to demonstrate non-inferiority of any fractional doses com-
pared to 5 DU IPV. Groups of BALB/c mice were immunized twice
(days 0 and 21) by either the ID or IM route with IPV (0.1–15 DU)
alone or admixed with dmLT (0.1–1 g). Two weeks after the ﬁnal
immunization, serum was  collected and analyzed for anti-PV IgG
by ELISA (Fig. 1A). A subset of these groups was also tested for virus
neutralizing antibodies by cell culture assay using Brunhilde PV1,
MEF-1 PV2, and Saukett PV3 (Fig. 1B). The neutralization assay is
considered the gold standard for assessing vaccine efﬁcacy [24],
and a log2 titer of ≥3 is considered protective. Our  results revealed
that un-adjuvanted fractional doses provided consistent levels of
serum IgG and neutralization titers by both the ID and IM routes
except at the lowest doses (≤0.5 DU). Un-adjuvanted ID delivery
did not appear to be superior to un-adjuvanted IM delivery at any
dose tested by either ELISA or virus neutralization; however, inclu-
sion of dmLT enhanced both serum IgG and neutralization titers
following ID immunization (dmLT was  not included with the IM
immunizations for this analysis). Speciﬁcally, anti-PV1 responses
induced by 1 DU IPV administered ID with dmLT exceeded the
responses to the control group receiving un-adjuvanted “full” dose
of 5 DU IPV administered IM.  Moreover, the neutralization titers
with 10 DU IPV + dmLT were signiﬁcantly higher than any level
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Fig. 2. Kinetics and longevity of poliovirus neutralization titers following IM or ID
immunizations. Mice were immunized (days 0, 21 and 42) with 1 DU IPV via IM or
ID  delivery with or without 0.1 g dmLT. Sera collected 2 weeks after each immu-
nization (days 14, 35 and 56) or 4 and 6 months (days 179 and 243) post-third
immunization were analyzed by in vitro virus neutralization against each poliovirus
strain: Brunhilde type-1 (top), MEF-1 type-2 (middle) and Saukett type-3 (bottom).
Values are median bars with interquartile range (n = 8–10 per time point). Signif-
icance is shown as *P ≤ 0.05, **P ≤ 0.01 or ***P ≤ 0.001 versus 1 DU IPV IM day 14912 E.B. Norton et al. / Vac
chieved with un-adjuvanted 10 DU by either the IM or ID route.
hroughout, groups receiving IPV + dmLT developed either higher
ntibody responses or were not statistically different from the 5 DU
M group (i.e., non-inferiority was achieved). The production of
erum neutralizing titers to Brunhilde PV1 is particularly important
ince PV1 is the least immunogenic component of IPV and this strain
s the most prominent cause of wild-type polio [2]. These results
ndicate that dmLT can promote dose-sparing by reducing the IPV
ose required for immunogenicity by at least ﬁve-fold, compared
o the IM and ID full-dose and fractional-dose controls. Individual
nimal responses are shown in Supplemental Fig. S1.
Supplementary Fig. S1 related to this article can be found, in the
nline version, at http://dx.doi.org/10.1016/j.vaccine.2015.02.069.
.2. Kinetics and longevity
We  next evaluated the kinetics and longevity of the virus neu-
ralization response to trivalent IPV (1 DU based on PV1 content)
lone or adjuvanted with 0.1 g dmLT by either the IM or ID route.
runhilde PV1 neutralization titers developed more rapidly and
ere maintained over a longer time period in animals immunized
ith IPV + dmLT compared to un-adjuvanted groups (Fig. 2). By
ontrast, MEF-1 PV2 and Saukett PV3 neutralization titers devel-
ped rapidly and were essentially equivalent through day 56 in
his model. However, as with PV1, neutralization titers against PV2
nd PV3 were maintained or even higher 4- or 6-months post-ﬁnal
mmunization (e.g., day 179 and 243) when dmLT was  included in
he vaccine. These results once again indicate that dmLT enhances
V1 neutralizing responses following either IM or ID delivery. In
ddition, longevity of all PV neutralizing responses was evident in
mLT-adjuvanted groups. Individual animal responses are shown
n Supplemental Fig. S2.
Supplementary Fig. S2 related to this article can be found, in the
nline version, at http://dx.doi.org/10.1016/j.vaccine.2015.02.069.
.3. Germinal center marker expression
Our kinetic response studies demonstrated that dmLT impacts
he peak and decay of the neutralizing antibody responses fol-
owing IPV immunization, suggesting altered development of
ntibody-secreting cells. Vaccine responses are generated in sec-
ndary lymphoid organs where antigen is presented to activated
-cells and B-cells within germinal centers expressing the GL7
arker [29,30]. To determine if dmLT enhances germinal center
ormation, we evaluated splenic CD4+ T-cells and B-cells for GL7
xpression in mice immunized IM with 1 DU IPV alone or ID with
 DU IPV with or without dmLT. Our results indicate that while all
mmunization groups have detectable expression of GL7+ T-cells
nd B-cells, only in groups receiving formulations containing dmLT
as this signiﬁcantly higher than in naïve mice (Fig. 3).
.4. Mucosal antibodies
Because mucosal immunity can protect against intestinal
oliovirus replication [31,32], we next evaluated induction of fecal
nti-PV IgA after vaccination. For these studies, we  ﬁrst ana-
yzed fecal samples from the IM and ID groups shown in Fig. 1
y ELISA against all three serotypes using the trivalent vaccine.
nalysis revealed that dmLT enhanced the number of group respon-
ers (40%) following ID immunization compared to un-adjuvanted
roups immunized IM or ID (0–29%, Fig. 4A); however, we  observed
oorer detection sensitivity than seen previously in our labora-
ory with IgA ELISAs for other antigens, implying interference in
PV antibody detection. For instance, fecal extracts from naïve
unimmunized) mice blocked detection of anti-IPV antibodies in
PV-positive serum (1 or 2) tested by anti-IPV IgG ELISA comparedvalues per virus serotype as indicated by solid lines using Dunn’s multiple compar-
ison  test.
to PBS dilution buffer. These results indicate that detection of fecal
anti-PV antibodies by ELISA is complicated by non-speciﬁc interac-
tions (Fig. 4B).
We next explored a modiﬁed immunoblot assay to test for anti-
PV fecal antibodies as an alternative to the ELISA. In this assay,
pre-loaded PV1, PV2 and PV3 antigens are detected upon incu-
bation of immunoblots with individual fecal samples diluted 1:5
with blocking buffer in 1 ml  total volume followed by anti-mouse
IgA. Immunoblot results showed the presence of IgA antibod-
ies in individual samples without the interference seen in the
ELISA (Fig. 5A). Using this method, we quantiﬁed (band integrated
band density (IDU) per ml  sample) anti-PV IgA in fecal samples
of mice immunized twice with 1 DU of IPV alone or with dmLT
by each route. Our results revealed that fecal IgA responses were
not detectable following IM immunization without adjuvant. How-
ever, un-adjuvanted ID immunization with IPV did elicit detectable
anti-IPV IgA in fecal pellets. The adjuvant dmLT both enhanced the
fecal anti-PV response following ID immunization and facilitated
E.B. Norton et al. / Vaccine 3
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Fig. 3. Germinal center marker expression by splenocytes following IM or ID
immunizations. Animals were immunized twice (days 0 and 21) with 1 DU trivalent
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ost hoc test.
nduction of fecal responses following IM immunization (Fig. 5A
nd B).
We  next conﬁrmed that fecal antibody responses were due, at
east in part, to local antibody production (and not rodent hep-
tobilliary recirculation of serum IgA into the intestines [33]) by
valuating different groups for ex vivo secretion of antibodies by
he intestinal secondary lymphoid tissue, PP. This assay has been
sed in other polio vaccine studies [34] to indicate that antibody
resence is due to secretion from PP-associated plasma cells and
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ig. 4. Poliovirus fecal IgA following IM or ID immunizations. Animals were immu-
ized twice (days 0 and 21) with the indicated dose of trivalent IPV via IM (5 animals
er group) or ID (7 animals per group) delivery route with or without dmLT adjuvant
0.1 g). (A) Fecal supernatants collected 2 weeks after the last immunization were
nalyzed for anti-poliovirus IgA antibodies by ELISA against the trivalent IPV vac-
ine. Values are ELISA units per ml  (EU/ml) for individual animals (n = 7+ per group)
ith % group responders indicated. (B) Poliovirus antibodies by IgG ELISA using pos-
tive mouse serum samples (serum 1 or serum 2) pre-incubated with dilution buffer
r  fecal supernatants from naïve animals.3 (2015) 1909–1915 1913
not derived directly from the serum. In our tests, no detectable
anti-PV antibodies appeared until at least 3 days incubation, but
we were able to demonstrate anti-IPV IgA in the supernatants of PP
tissue cultured for 7 days ex vivo and correlate that with fecal IgA
immunoblot results (Fig. 5B–D). Taken together, our mucosal anal-
yses indicate signiﬁcant mucosal responses following parenteral
immunization by either the IM or ID route when dmLT is included
as an adjuvant in the formulation.
4. Discussion
Global polio eradication is close to being achieved thanks to
the efforts of widespread vaccination programs; however, the
existing live-attenuated oral vaccine will soon be replaced by a non-
replicating vaccine. Unfortunately, the use of IPV is cost-prohibitive
based on the current full dose schedule. In order to reduce the cost
of IPV immunization, strategies to reduce the required vaccine dose
are being investigated [6,7,28,34–36]. In addition, OPV provides
a certain level of mucosal immunity [5,32] that has not yet been
achieved by a parenteral immunization with IPV. The objective of
the current study was to evaluate whether ID or IM delivery of IPV
in combination with the adjuvant dmLT could reduce the required
dose or number of doses of an existing IPV vaccine and whether
this novel adjuvant could promote mucosal immunity following
parenteral immunization.
We ﬁrst compared un-adjuvanted fractional dose IPV by both
ID and IM delivery. Fractional doses of IPV delivered either ID or
IM promoted virus-neutralizing titers for PV2 and PV3, but not
PV1. In our study, ID immunization with IPV alone was  not supe-
rior to IM for induction of serum anti-IPV antibodies, in contrast
to earlier reports by other investigators [28,36]. We  held the vol-
ume of IM and ID injection constant (50 l) to avoid the variable of
delivery volume. This volume may not be optimal for ID delivery in
mice, as antigen loss may  occur from higher dermal pressure (with
higher volumes). We  also utilized the Mantoux technique, although
other ID delivery devices and technology show promise for pro-
moting immune responses over this classic ID technique [26,27]
and warrant further study for ID delivery of IPV and other vac-
cines. In contrast to serum responses, un-adjuvanted ID delivery
did promote increased fecal anti-PV IgA that was  not seen with IM
delivery.
We further demonstrated that dmLT enhances serum anti-PV
neutralizing antibodies with fractional IPV doses by either IM or
ID delivery. Using 5 DU for an equivalent “full” mouse dose, dmLT
achieved at least ﬁve-fold dose sparing above non-adjuvanted frac-
tional doses. These responses were most noticeable with the PV1
strain of the vaccine, likely because PV1 is the least immunogenic
serotype in IPV and exhibits lower neutralizing antibody responses
even with higher DU doses than PV2 and PV3 (which develop
robust d35 responses with unadjuvanted fractional doses). How-
ever, when longevity of response was evaluated, dmLT-adjuvanted
groups displayed higher levels of PV1, PV2 and PV3 neutralizing
titers (out to 243 days). dmLT also induced higher levels of mucosal
immunity, as deﬁned by fecal IgA and intestinal anti-PV IgA secre-
tion, when included in IPV immunization by either the ID or IM
route. This ﬁnding has potential implications for reformulating a
fractional dose IPV vaccine, as increasing intestinal IgA correlates
with decline in intestinal virus replication [32] and pre-existing IgA
levels in elderly humans better protects against virus fecal shedding
after challenge [31]. Moreover, in contrast with OPV, intramuscular
injection with IPV does not normally induce mucosal antibodies, so
these ﬁndings are particularly important given the role intestinal
immunity plays in reduction of disease transmission in the commu-
nity in addition to reducing viral replication in the individual. Our
ﬁndings correlate with other immunization studies that show dmLT
1914 E.B. Norton et al. / Vaccine 33 (2015) 1909–1915
Fig. 5. Anti-poliovirus fecal IgA immunoblot and intestinal PP IgA following IM or ID immunizations. Animals were immunized twice (days 0 and 21) with 1 DU IPV via IM
or  ID delivery route with or without 1 g dmLT. Two weeks after the ﬁnal immunization, fecal pellet extracts were collected and/or intestinal PP tissue excised and cultured
in  vitro for detection of IgA antibody secretion. (A) Immunoblots loaded with 10 DU poliovirus type-1, -2 or -3 (e.g., PV1, PV2, PV3, as shown in top labels) were probed
for  anti-poliovirus IgA using fecal pellet extracts from individual mice (1–20) vaccinated with formulations shown in bottom labels. (B) These bands were quantiﬁed for
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y skin administration helps achieve mucosal immunity; dmLT in a
ranscutaneous vaccine against Haemophilus inﬂuenzae otitis media
mproved clearance of ongoing bacterial bioﬁlms and promoted
ucosal immune responses in the inner ear in a chinchilla model
16,17]. Similarly, dmLT addition to an ID vaccine against Shigella
romoted IgG in pulmonary secretions and protection from lethal
ulmonary challenge in a mouse model [15].
Germinal center formation is key for development of T-
ependent immunity and optimal antibody responses [29,30].
erminal center development was initially characterized using
holera toxin [37] and GL7-induction has been found in related,
holera toxin-derived adjuvants [38]. In our study, we  were able
o demonstrate that dmLT enhances germinal center formation in
mmunized mouse spleens, shown as increased GL7 expression
n T-cells and B-cells. These observations help explain how this
djuvant improves magnitude and duration of immunity after IPV
accination.
. Conclusion
Our study revealed that dmLT is a potential adjuvant for either
M or ID delivery of IPV. Inclusion of dmLT in IPV immunizations
llows antigen dose sparing and enhances mucosal immunity and
ongevity of anti-PV responses following either IM or ID delivery.
uture expansion of these studies to other models (rodent, NHP) or
uman clinical studies could further demonstrate the potential of
mLT as an adjuvant in a modiﬁed IPV vaccine strategy and thereby
ake another step toward achieving the global eradication of
olio.l animals (symbols) with group means (bars). (C) Comparison for groups of fecal
estinal PP antibody secretion. Values are mean + SEM. (D) Correlation between fecal
n’s Rank Order Correlation Coefﬁcient (r) analysis.
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